Arcutis Submits Zoryve sNDA to FDA for Infants, Babies
Arcutis has filed a supplemental NDA with the FDA to extend ZORYVE (roflumilast) cream 0.05% to infants aged 3...
Ocular Therapeutix Announces May Conference Participation
Ocular Therapeutix will use May’s ophthalmology and investor meetings to showcase its retina ambitions, headlined by the first Phase...
Surging Growth: Idorsia’s QUVIVIQ Sales Soar 74% in Q1
Idorsia opened 2026 with a 74% year-over-year jump in QUVIVIQ net sales to CHF 44 million, fresh Phase 2...
Icovamenib’s Surging C-Peptide Victory in Type 1 Diabetes
Biomea Fusion reported 52-week data from its Phase 2, open-label COVALENT-112 trial in type 1 diabetes showing that a...
Dark Horse & Porton Advanced Streamline IITs in China
Dark Horse Consulting Group and Porton Advanced have signed a memorandum of understanding to create an integrated pathway for...
Codexis Announcing First Quarter 2026 Financial Results
Codexis will report first-quarter 2026 results on May 7 after market close, with a management call to follow. For...
TheiaLife Taps Ruggia as CEO for Oral Myopia Therapy
Theialife has appointed Thomas Ruggia as President and CEO as it readies Phase 3 development for ND10, an oral...
Agomab Reports 2025 Financials, Confirms 2026 Outlook
Agomab Therapeutics has extended its cash runway into the first half of 2029 after raising $208 million in gross...
Trevi Therapeutics to Participate in Upcoming May Events
Trevi Therapeutics is lining up a concentrated May roadshow around Haduvio, its oral extended-release nalbuphine for chronic cough, with...
Clinuvel’s Pivotal Vitiligo Study: Final EMA Advice Here
Clinuvel has secured final scientific advice from the European Medicines Agency on its pivotal Phase III CUV107 trial evaluating...